Clinical Insights
Expert video commentary and evidence-based perspectives from leading psychiatrists — with key takeaways you can apply in clinical practice.
JCP Webinar
▶ Video
GLP-1 Receptor Agonists for Long-Term Kidney Protection
October 23, 2026
In this webinar, Balwinder Singh, MD, and Raman Baweja, MD, describe emerging evidence on GLP-1 receptor agonists for long-term kidney protection in bipolar disorder with chronic kidney disease. They discuss the real-world cohort findings on kidney replacement therapy and lithium monitoring considerations raised during the Q and A.
Author Insight
▶ Video
Cannabis Use and Early Psychiatric Rehospitalization in Young Adults With Bipolar or Psychotic Disorders
October 15, 2026
Justine Perino, MD, discusses a historical cohort study assessing whether cannabis use at admission is associated with psychiatric rehospitalization after discharge in young adults with bipolar or psychotic disorders. The video focuses on the timing of readmission risk and the first three months after discharge.
Expert Commentary
▶ Video
Negative Symptoms May Predict Who Responds to Xanomeline-Trospium in Schizophrenia
October 8, 2026
Mike Halassa describes negative symptoms in schizophrenia and discusses clinical and post-hoc evidence that potentially suggests negative symptoms may be a useful clinical feature to look for when considering xanomeline-trospium.
Original Research
▶ Video
Impact of Cannabis Use on Time to Psychiatric Rehospitalization in Young Adults With Bipolar and Psychotic Disorders: A Survival Analysis
September 28, 2026
In young adults with psychotic or bipolar disorders, cannabis use is a predictor of early psychiatric readmission. The first 3 months post-discharge are critical for follow-up and intervention.
Author Insights
▶ Video
Combining Clozapine and Xanomeline/Trospium Chloride: Mechanisms of Action and the Genesis of Catatonia
September 25, 2026
Warren Cheng, MD Candidate, on a case where abruptly stopping clozapine while continuing Cobenfy (xanomeline-trospium) preceded severe catatonia, and the rebound-cholinergic hypothesis that may explain the risk as Cobenfy use grows.
Academic Highlights
▶ Video
Treatment-Resistant Depression as a Dynamic Continuum: A Consensus Panel Report on Mechanism-Informed Pharmacologic Sequencing
September 23, 2026
The panelists reframe treatment-resistant depression as a dynamic continuum and provide a four-stage framework that takes clinicians from initial detection through high-acuity interventions.
Academic Highlights
▶ Video
Targeted Treatment of Agitation in Alzheimer’s Dementia: Prioritizing Function and Safety Over Sedation and Other Serious Harms
September 22, 2026
The panelists provide recommendations to give primary care clinicians a practical, evidence-based guide for managing agitation in Alzheimer's dementia, and the confidence to apply it.
Clinical Pearls
The Reported Strength of Association Between Symptoms and Quality of Life Depends on How Quality of Life Is Defined and Measured
September 22, 2026
Symptoms correlate modestly with quality of life in schizophrenia, but the reported strength depends on the measure. Pooled findings from 56 studies.
Video Abstract
▶ Video
Population Pharmacokinetics and Dosing Simulations for Paliperidone Palmitate 351 mg as Alternative Maintenance Doses in Patients With Schizophrenia or Schizoaffective Disorder
September 18, 2026
Jonathan M. Meyer, MD, and Leslie Citrome, MD, present a JCP video abstract on pharmacokinetic simulations for paliperidone palmitate 351 mg, and what its every-4, -6, and -8-week dosing options could mean for schizophrenia maintenance.
Insights
▶ Video
Population Pharmacokinetics and Dosing Simulations for Paliperidone Palmitate 351 mg as Alternative Maintenance Doses in Patients With Schizophrenia or Schizoaffective Disorder
September 16, 2026
This analysis suggests that maintenance doses of paliperidone palmitate 351 mg at different dosing intervals may offer additional treatment options for clinical use.
